Introduction: India’s pharmaceutical and specialty chemical manufacturing sectors are undergoing significant changes as global supply chains, technology, domestic demand and regulatory requirements evolve. India has already established a strong position in generic medicines , pharmaceutical formulations, drug intermediates and chemical manufacturing. The next phase is increasingly focused on expanding domestic production, developing higher-value products and strengthening supply-chain resilience. Growing Demand for Pharmaceutical Intermediates Pharmaceutical intermediates remain a significant part of India’s manufacturing ecosystem. These chemical compounds are used in the production of active active ingredients and other pharmaceutical products. Growing pharmaceutical production in India and overseas supports demand for intermediates. The increase in bulk drug and drug intermediate exports during Q1 FY27 demonstrates the expanding role of this segment in India's pharmaceutical tr...
Introduction India is entering an important phase in pharmaceutical manufacturing, with increasing attention on domestic API production, supply chain resilience, advanced manufacturing and global competitiveness. Active Pharmaceutical Ingredients, or APIs, are the key substances responsible for the therapeutic action of medicines. Their availability directly influences the production of finished pharmaceutical formulations. India has traditionally been a major global pharmaceutical manufacturing hub , but dependence on imported APIs, Key Starting Materials (KSMs) and Drug Intermediates (DIs) has highlighted the need for a stronger domestic supply base. In response, the Indian government has introduced several initiatives designed to expand local manufacturing capacity and reduce supply vulnerabilities. As of December 2025, 38 projects covering 28 notified products had been commissioned under the PLI scheme for bulk drugs, creating approximately 56,800 tonnes per year of domestic m...